Histone deacetylase inhibitors: Development as cancer therapy

Novartis Foundation Symposium

Volumn 259, Issue , 2004, Pages 269-284

  Marks, Paul A ^a   Richon, Victoria M ^b   Kelly, Wm Kevin ^a   Chiao, Judy H ^b   Miller, Thomas ^b   Pelicci, ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Aton Pharma Inc   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE;

ARTICLE; CLASSIFICATION; DRUG ANTAGONISM; HUMAN; LARYNX TUMOR; LUNG; LUNG TUMOR; METASTASIS; NEOPLASM; PATHOLOGY;

HISTONE DEACETYLASES; HUMANS; LARYNGEAL NEOPLASMS; LUNG; LUNG NEOPLASMS; NEOPLASMS;

EID: 2942724589     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (51)

1. Boivin AJ, Momparler LF, Hurtubise A, Momparler RL 2002 Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 13:869-874
2. Bouchain G, Leit S, Frechette S et al 2003 Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors. J Med Chem 46:820-830
3. Butler LM, Zhou X, Xu W-S et al 2002 The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99:11700-11705
4. Carducci M, Bowling MK, Eisenberger MA et al 1997 Phenylbutyrate (PB) for refractory solid tumors: phase I clinical and pharmacologic evaluation of intravenous and oral PB. Anticancer Res 17:3972-3973
5. Chang SM, Kuhn JG, Robins HI et al 1999 Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 17:984-990
6. Curtin ML, Garland RB, Heyman HR et al 2002 Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC). Bioorg Med Chem Lett 12:2919-2923
7. Della Ragione F, Criniti V, Della-Pietra V 2001 Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett 499:199-204
8. De Ruijter AJ, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg AB 2003 Histone deacetylases: characterisation of the classical HDAC family. Biochem J 370:737-749
9. Finnin MS, Donigian JR, Cohen A et al 1999 Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193
10. Freiman RN, Tjian R 2003 Regulating the regulators: lysine modifications make their mark. Cell 112:11-17
11. Frey RR, Wada CK, Garland RB et al 2002 Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett 12:3443-3447
12. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S 2001 Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 98:87-92
13. Furumai R, Matsuyama A, Kobashi N et al 2002 FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62:4916-4921
14. Gilbert J, Baker SD, Bowling MK et al 2001 A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7:2292-2300
15. Gottlicher M, Minucci S, Zhu P et al 2001 Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978
16. Grozinger CM, Schreiber SL 2002 Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 9:3-16
17. Guan Z, Giustetto M, Lomvardas S et al 2002 Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell 111:483-493
18. Jenuwein T, Allis CD 2001 Translating the histone code. Science 293:1074-1080
19. Jones PA, Baylin SB 2002 The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428
20. Keer H, Reid T, Sreedharan S 2001 Pivanex activity in refractory non-small cell lung cancer, a phase II study. Proc Am Soc Clin Oncol 314a
21. Kelly WK, O'Connor OA, Marks PA 2002a Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 11:1695-1713
22. Kelly WK, O'Connor O, Richon VM et al 2002b A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor of suberoylanilide hydroxamic acid (SAHA). 14th EORTC-NCI-AACR, November 2002, Frankfurt (abstr 286, available in Eur J Cancer 38:88)
23. Kelly W, Richon VM, O'Connor O et al 2003 Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid (SAHA) administered intravenously. Clin Canc Res 9:3578-3588
24. Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D 2001 Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 11:162-166
25. Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S 1999 Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18:2461-2470
26. Kouzarides T 2000 Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19:1176-1179
27. Lagger G, O'Carroll D, Rembold M et al 2002 Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21:2672-2681
28. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK 2001 Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202
29. McKinsey TA, Zhang CL, Olson EN 2001 Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev 11:497-504
30. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS 2001 Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741
31. Piekarz RL, Robey R, Bakke S, Sandor V, Wilson W, Bates S 2001 Histone deacetylase inhibitor for the treatment of peripheral or cutaneous T-cell lymphoma. ASCO 232b
32. Polevoda B, Sherman F 2002 The diversity of acctylated proteins. Genome Biol 3:REVIEWS0006
33. Prakash S, Foster BJ, Meyer M et al 2001 Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs 19:1-11
34. Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG 1999 Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80:1252-1258
35. Richon VM, Emiliani S, Verdin E et al 1998 A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3003-3007
36. Richon VM, Sandhoff TW, Rifkind RA, Marks PA 2000 Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014-10019
37. Saito A, Yamashita T, Mariko Y et al 1999 A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96:4592-4597
38. Sandor V, Bakke S, Robey RW et al 2002 Phase I trial of the historic deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8:718-728
39. Scott GK, Marden C, Xu F, Kirk L, Benz CC 2002 Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol Cancer Ther 1:385-392
40. Singh SB, Zink DL, Liesch JM et al 2002 Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal alpha-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities. J Org Chem 67:815-825
41. Spotswood HT, Turner BM 2002 An increasingly complex code. J Clin Invest 110:577-582
42. Su GH, Sohn TA, Ryu B, Kern SE 2000 A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res 60:3137-3142
43. Suzuki H, Gabrielson E, Chen W et al 2002 A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31:141-149
44. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A 2001 Histone acetylation and disease. Cell Mol Life Sci 58:728-736
45. Turner BM 2002 Cellular memory and the histone code. Cell 111:285-291
46. Van Lint C, Emiliani S, Verdin E 1996 The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation. Gene Expr 5:245-253
47. Vrana JA, Decker RH, Johnson CR et al 1999 Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18:7016-7025
48. Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG 2001 Histone acetylation and the cell-cycle in cancer. Front Biosci 6:D610-D629
49. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP 1998 Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase J Natl Cancer Inst 90:1621-1615
50. Yoshida M, Kijima M, Akita M, Beppu T 1990 Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174-17179
51. Zhang Y, Reinberg D 2001 Transcription regulation by histone methylation:interplay between different covalent modifications of the core histone tails. Genes Dev 15:2343-2360